Harbin Pharmaceutical opened higher on July 15 and hit its daily limit up within one minute, closing at 4.49 yuan per share, up 10.05 percent, marking four consecutive trading days of limit up. In terms of news, the company disclosed on July 14 the adjustment of its products in the National Essential Drug List. A total of 118 product specifications were included in the 2026 edition of the National Essential Drug List, among which six new varieties with ten specifications were added, including human granulocyte colony-stimulating factor injection and penicillin sodium for injection, while one variety was removed. On the same day, the pharmaceutical sector strengthened overall, with BioValley surging 30 percent intraday to hit its limit up, currently trading at 8.87 yuan per share, up 28.18 percent. In addition, data from the National Medical Products Administration shows that in the first six months of this year, China recorded 81 out-licensing deals for innovative drugs, with a total transaction value of approximately 110 billion US dollars, already reaching 80 percent of the total out-licensing transaction value for the full year 2025, setting a new historical high.
Harbin Pharmaceutical Group Co Ltd118 product specifications included in National Essential Drug List, with 6 new varieties added.